

EFFECTIVE DATE: 12|01|2014

POLICY LAST UPDATED: 11|01|2016

OVERVIEW

Collagenases are enzymes that digest native collagen and are being evaluated for treatment of fibroproliferative disorders such as Dupuytren's contracture and Peyronie's disease. Injection with clostridial collagenase is intended to provide a non-operative treatment option for fibroproliferative disorders.

MEDICAL CRITERIA

BlueCHiP for Medicare and Commercial Products

Injectable clostridial collagenase is covered for all members who meet all of the following criteria:

- Adult patients with Dupuytren's contracture with
 - a palpable cord, and
 - functional impairment, and
 - fixed-flexion contractures of the metacarpophalangeal joint or proximal interphalangeal joint of 20 degrees or more excluding the thumb.

PRIOR AUTHORIZATION

BlueCHiP for Medicare and Commercial Products

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial products and is obtained via the online tool for participating providers. See the Related Policies section.

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Injectable clostridial collagenase is considered medically necessary for Dupuytren's contracture, for up to three injections at intervals of at least thirty-days, when the medical criteria are met.

Injectable clostridial collagenase is considered not medically necessary for all other indications including Peyronie's disease due to the lack of peer-reviewed medical literature which supports use.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable "Services Not Medically Necessary" benefit/coverage.

BACKGROUND

Clostridial collagenase is a bacterial collagenase derived from *Clostridium histolyticum* that has been evaluated for the treatment of fibroproliferative disorders such as Dupuytren contracture and Peyronie disease.

Injection with clostridial collagenase is intended to provide a nonoperative treatment option for fibroproliferative disorders. Fibrotic tissue disorders, characterized by excessive collagen deposits, can affect the musculoskeletal system, causing pain and limiting movement and reducing joint range of motion. Examples of fibroproliferative disorders include Dupuytren disease, Peyronie disease, and adhesive capsulitis.

The mechanisms that contribute to the pathology are poorly understood. In Dupuytren disease, collagen deposition in nodules and cords in the palm and fingers results in pitting of the overlying cutis and flexion contractures. The standard of care for Dupuytren disease is surgery, most commonly open fasciectomy. Other surgical procedures are percutaneous fasciotomy and needle fasciotomy. Surgery is recommended in

patients with functional impairment and metacarpophalangeal (MCP) joint contractures of 30° or more. There is no effective pharmacotherapy.

Adhesive capsulitis or “frozen shoulder” is treated with physiotherapy and mobilization in combination with analgesics or nonsteroidal anti-inflammatory drugs. Corticosteroid injection is used with caution. The prevalence of Dupuytren disease and adhesive capsulitis is estimated at 3% to 6% and 2% to 3%, respectively, in the general population and increases with advancing age. Both conditions are more common in patients with diabetes or thyroid disease. Dupuytren disease is more common in men, and adhesive capsulitis more common in women.

Peyronie disease is the development of abnormal scar tissue, or plaques, in the tunica albuginea layer of the penis causing distortion, curvature, and pain, usually during erection. It occurs in 3% to 9% of men, most commonly between the ages of 45 and 60 years. In some cases, plaque does not cause severe pain or curvature, and the condition resolves on its own. In severe cases, erectile dysfunction can occur. The goal of treatment is to reduce pain and maintain sexual function. Treatments in early stages (before calcification) include vitamin E or para-aminobenzoate tablets (e.g., Potaba), although studies of oral therapies demonstrate inconsistent benefit. Intralesional injection therapy consisting of injection of interferon- α -2b or calcium channel-blockers (e.g., verapamil) is the current standard of therapy.² Surgical procedures involve the excision (removal) of hardened tissue and skin graft, the removal or pinching (plication) of tissue opposite the plaque to reduce curvature (called the Nesbit procedure), a penile implant, or a combination of these.

Adhesive capsulitis or “frozen shoulder” is treated with physical therapy and mobilization in combination with analgesics or nonsteroidal anti-inflammatory drugs. Corticosteroid injection is used with caution. The prevalence of Dupuytren disease and adhesive capsulitis is estimated at 3% to 6% and 2% to 3%, respectively, in the general population and increases with advancing age. Both conditions are more common in patients with diabetes or thyroid disease. Dupuytren disease is more common in men, and adhesive capsulitis more common in women.

Clostridial collagenase histolyticum is an enzyme produced by the bacterium *Clostridium histolyticum*, which has the physiologic effect of breaking down collagen. It has been developed and marketed pharmacologically as a treatment for disorders associated with collagen overdevelopment.

For patients with Dupuytren contracture, the evidence from clinical trials suggests that injectable clostridial collagenase provides short-term release of contracture. A comparison of overall outcomes compared with surgical intervention may be useful; however, randomized studies with direct comparisons are not available. Some nonrandomized studies comparing clostridial collagenase with surgery report similar outcomes with faster return-to-work and return-to-usual activities rates with clostridial collagenase, but 1 study reported poorer contraction improvement but lower adverse event rates. Evidence on long-term recurrence rates is somewhat limited, but 3- and 5-year follow-ups from 1 large registry reported high recurrence rates (47% at 5 years). Although clostridial collagenase is associated with the potential benefit of being a less-invasive treatment for Dupuytren contracture, gaps in the evidence base related to treatment durability exist. The evidence is insufficient to determine the effects of the technology on health outcomes.

For other disorders, there is less evidence. Based on the available evidence and clinical input, injection of this agent clostridial collagenase is considered not medically necessary for all other treatment indications, including Peyronie disease and adhesive capsulitis as there is insufficient peer-reviewed literature that demonstrates that the service is effective.

CODING

BlueCHiP for Medicare and Commercial Products

The following codes are considered medically necessary when the medical criteria are met:

20527 J0775

The CPT code for the manipulation of the cord is only covered if the injection is covered:
26341

It is considered incorrect coding to report the injection with the following CPT code:
20550

RELATED POLICIES

Preauthorization via Web-Based Tool for Procedures

PUBLISHED

Provider Update, January 2017
Provider Update, January 2016
Provider Update, January 2015
Provider Update, June 2013
Provider Update, October 2012
Provider Update, April 2011
Provider Update, July 2010

REFERENCES

1. Hellstrom WJ. Medical management of Peyronie's disease. *J Androl.* Jul-Aug 2009;30(4):397-405. PMID 18974422
2. Food and Drug Administration (FDA). Xiaflex: Label. http://www.endo.com/File%20Library/Products/Prescribing%20Information/Xiaflex_prescribing_information.html#LINK_a7d1f7e8-79cf-49aa-8e76-3ddc035530db. Accessed September 26, 2016
3. Peimer CA, Wilbrand S, Gerber RA, et al. Safety and tolerability of collagenase Clostridium histolyticum and fasciotomy for Dupuytren's contracture. *J Hand Surg Eur Vol.* Apr 29 2014. PMID 24698851
4. Witthaut J, Bushmakina AG, Gerber RA et al. Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study. *Clin Drug Investig* 2011; 31(11):791-8
5. Hurst LC, Badalamente MA, Hentz VR et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. *N Engl J Med* 2009; 361(10):968-79
6. Chen NC SR, Shauver MJ et al. A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture. *Hand* 2011; 2011(September 28):6(3):250-5
7. Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. *J Hand Surg Am* 2007; 32(6):767-74.
8. McGrouther DA, Jenkins A, Brown S, et al. The efficacy and safety of collagenase clostridium histolyticum in the treatment of patients with moderate Dupuytren's contracture. *Curr Med Res Opin.* Apr 2014;30(4):733-739. PMID 24397625
9. Raven RB, 3rd, Kushner H, Nguyen D, et al. Analysis of Efficacy and Safety of Treatment With Collagenase Clostridium histolyticum Among Subgroups of Patients With Dupuytren Contracture. *Ann Plast Surg.* Mar 18 2013. PMID 23511746

10. Smeraglia F, Del Buono A, Maffulli N. Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review. Br Med Bull. Jun 2016;118(1):149-158. PMID 27151958

11. Brazzelli M, Cruickshank M, Tassie E, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation. Health Technol Assess. Oct 2015;19(90):1-202. PMID 26524616

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

